Clinical trials
Phase 3 Bronchitis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2024 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 19 |
| Unknown status | 5 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ahn-Gook Pharmaceuticals Co.,Ltd | 4 |
| AstraZeneca | 2 |
| Daewon Pharmaceutical Co., Ltd. | 2 |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2 |
| Engelhard Arzneimittel GmbH & Co.KG | 1 |
| Grünenthal GmbH | 1 |
| Hanlim Pharm. Co., Ltd. | 1 |
| Hospital Universitari Vall d'Hebron Research Institute | 1 |
| Hyundai Pharmaceutical Co., LTD. | 1 |
| Inmunotek S.L. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bronchitis | 27 |
| Cough | 5 |
| Pulmonary Disease, Chronic Obstructive | 5 |
| Bronchitis, Chronic | 4 |
| Emphysema | 3 |
| Respiratory Tract Infections | 3 |
| Bronchiolitis Obliterans Syndrome | 2 |
| Bronchial Diseases | 1 |
| Bronchial Spasm | 1 |
| Bronchiolitis | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.